To Evaluate Efficacy of Ursodeoxycholic Acid (UDCA) for the Prevention of Gallstone Formation After Gasterectomy

• Status: Recruiting
• Trial end date: 2022-09-30
• Target enrollment: 0
• Participant gender: All

Summary

Of those patients who participated in PEGASUS-D FAS clinical trial, patient must sign the informed consent form in order to participate in this extension study.

The medical records of the patients will be reviewed throughout the study.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Daewoong Pharmaceutical Co. LTD.
• Treatments: Ursodeoxycholic Acid

Criteria

Inclusion Criteria:

• The patient who participated in PEGASUS-D Clinical trial, and is willing to participate in this study by signing the informed consent form.

• Or the patient whose medical records can be accessed according to site's consent exemption criteria.

Exclusion Criteria:

• The patient who the investigator finds it difficult to participate in this clinical trial.